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Increasing plasma norepinephrine (NE) levels as a measure of adrenergic activity herald worsening of heart failure (HF) in patients with reduced 
LV ejection fractions. We assessed the role of NE in contributing to new onset atrial fibrillation (AF) and to new onset (NAF) prevention by the beta-
blocker/sympatholytic agent in patients with advanced HF in the 2708 patient BEST trial. Baseline (Bsl) NE levels measured by HPLC/ECD were 
available in 1868 of the 2392 enrolled patients who did not have AF at Bsl (SR). New onset AF was assessed from AE/SAE case report forms as well 
as routinely measured ECGs in patients not in AF on study entry. In the 2392 patient cohort without AF at baseline there were 115/1190 (9.7%) new 
onset AF (NAF) episodes patients in the placebo group, and 75/1202 (6.2%) in the bucindolol group study (hazard ratio (95% C.I.s) = 0.59 (0.44, 
0.79), p =0.0004). As shown in the table, baseline NE was higher among patients with new onset AF compared to patients who did not develop AF 
(NAF 530281 vs. no AF 498328 pg/ml, p = 0.015). NE at three months decreased in the bucindolol subgroups vs. placebo subgroups. 
Group Bsl NE (pg/ml) NE 3 mos (pg/ml)
SR Bsl/no AF SR Bsl/NAF SR Bsl/no AF SR Bsl/NAF
Placebo
482307
n = 839
493258
n = 87
21±10.6‡
n = 663
88±46
n = 75
Bucindolol
514344*
n = 880
581305†
n = 62
-74±11.9‡,*
n = 694
-129±49‡,*
n = 49
All
498328
n = 1719
530281†
n = 149
-28±8.1
n = 1357
2.0±35
n = 124
Variance is SD for Bsl, SEM for ; *p <0.05 vs. placebo, †p<0.05 vs. no AF; ‡p<0.05 vs. Bsl
Conclusions: 1) New Onset AF was associated with a higher NE at baseline; 2) Bucindolol was associated with a lowering of three month NE and 
the risk of developing new onset AF.
